Just thought some people might be interested in the following patent.  This
patent uses human lactoferrin to treat asthma.  Well actually the human
lactoferrin is a recombinant made from a filamentous fungi--Aspergillus.
They believe the recombinant is equivalent to human breast milk lactoferrin.
This patent has as  inventors, Orla Conneely and Pauline Ward; and the
assignee is Baylor College of Medicine.  Baylor College is associated with a
biotech company, Agennix, which  sells recombinant human lactoferrin.   I
find it surprising that there are studies around that suggest that
breastfeeding causes asthma....particularly since so few infants are
exclusively breastfeed in the USA.  How do these studies define
breastfeeding?  If a baby is getting both formula and breastmilk, how does
one determine that it is breastmilk alone that is the culprit?  Of course,
now we have the supposed cure for asthma--a dose of recombinant human
lactoferrin that is just like human breast milk in its ability to stop the
inflammatory response...one might wonder if the true cure might be that
infants get only human milk but I guess that is a little too much to ask for
in this country.
Valerie W. McClain, IBCLC


http://www.uspto.gov/patft/index.html

Patent # 6111081
entitled "Lactoferrin variants and uses thereof."

"F. Pharmaceutical Formulation and Routes of Administration

For therapeutic use, the lactoferrin variants or portions thereof chosen can
be administered by any conventional means available for use in conjunction
with pharmaceuticals, either as individual therapeutic agents or in a
combination of therapeutic agents. Each can be administered alone but is
generally administered with a pharmaceutical carrier selected on the basis of
the chosen route of administration and standard pharmaceutical practice. The
pharmaceutical compositions of the invention may be adapted for oral,
parenteral, topical or rectal administration, or as inhalant, and may be in
unit dosage form, in a manner well known to those skilled in the
pharmaceutical art. Parenteral administration includes but is not limited to,
injection subcutaneously, intravenously, intraperitoneally or
intramuscularly.

Treatment with the active ingredient may begin at any time after the
indication to be treated, e.g., infections, or skin disorders, e.g.,
psoriasis, contact dermatitis, UV-induced inflammation, infant diaper rash,
asthma, arthritis, and the like, is diagnosed. Preferably, treatment is
commenced as a prophylactic or at early stages of the disease, in order to
prevent massive infection or inflammation in the first place. Typically,
treatment will continue until the disorder is cured. In cases of chronic
diseases, such as psoriasis, asthma or arthritis, or in cases of continued
exposure to an allergen, the treatment may have to be extended beyond the
cure of the symptoms.

The dose administered will, of course, vary depending upon known factors,
such as (1) the pharmacodynamic characteristics of the particular lactoferrin
product and its mode and route of administration, (2) the age, health, height
and weight of the recipient, (3) the nature and extent of the symptoms, (4)
the kind of concurrent treatment(s), (5) the frequency of treatment(s), and
(6) the effect desired. A daily dose of active ingredient can be determined
by those skilled in the art depending on the above factors."






             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html